Logo image of 22UA.DE

BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis

FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR

101.6  -2.5 (-2.4%)

Fundamental Rating

4

22UA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. 22UA has an excellent financial health rating, but there are some minor concerns on its profitability. 22UA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

22UA had negative earnings in the past year.
In the past year 22UA had a positive cash flow from operations.
Of the past 5 years 22UA 4 years were profitable.
In multiple years 22UA reported negative operating cash flow during the last 5 years.
22UA.DE Yearly Net Income VS EBIT VS OCF VS FCF22UA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5B 10B

1.2 Ratios

The Return On Assets of 22UA (-2.08%) is better than 72.22% of its industry peers.
With a decent Return On Equity value of -2.44%, 22UA is doing good in the industry, outperforming 72.22% of the companies in the same industry.
Industry RankSector Rank
ROA -2.08%
ROE -2.44%
ROIC N/A
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A
22UA.DE Yearly ROA, ROE, ROIC22UA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 50 100 150

1.3 Margins

22UA's Profit Margin has improved in the last couple of years.
22UA has a Gross Margin of 87.71%. This is amongst the best in the industry. 22UA outperforms 83.33% of its industry peers.
22UA's Gross Margin has been stable in the last couple of years.
22UA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
22UA.DE Yearly Profit, Operating, Gross Margins22UA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 22UA has less shares outstanding
22UA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 22UA is higher compared to a year ago.
22UA.DE Yearly Shares Outstanding22UA.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
22UA.DE Yearly Total Debt VS Total Assets22UA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B

2.2 Solvency

22UA has an Altman-Z score of 6.50. This indicates that 22UA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 22UA (6.50) is better than 91.67% of its industry peers.
The Debt to FCF ratio of 22UA is 0.25, which is an excellent value as it means it would take 22UA, only 0.25 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 22UA (0.25) is better than 98.61% of its industry peers.
22UA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
22UA's Debt to Equity ratio of 0.01 is amongst the best of the industry. 22UA outperforms 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.25
Altman-Z 6.5
ROIC/WACCN/A
WACC7.08%
22UA.DE Yearly LT Debt VS Equity VS FCF22UA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 7.33 indicates that 22UA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.33, 22UA belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
A Quick Ratio of 7.21 indicates that 22UA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.21, 22UA belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 7.21
22UA.DE Yearly Current Assets VS Current Liabilites22UA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B

More info and screens

3

3. Growth

3.1 Past

22UA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.52%.
22UA shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 279.64% yearly.
22UA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -54.07%.
The Revenue has been growing by 97.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
Revenue 1Y (TTM)-54.07%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%

3.2 Future

The Earnings Per Share is expected to decrease by -17.80% on average over the next years. This is quite bad
The Revenue is expected to decrease by -4.48% on average over the next years.
EPS Next Y-185.35%
EPS Next 2Y-70.23%
EPS Next 3Y-42.65%
EPS Next 5Y-17.8%
Revenue Next Year-38.23%
Revenue Next 2Y-22.56%
Revenue Next 3Y-15.83%
Revenue Next 5Y-4.48%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
22UA.DE Yearly Revenue VS Estimates22UA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
22UA.DE Yearly EPS VS Estimates22UA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

22UA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 22UA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
22UA.DE Price Earnings VS Forward Price Earnings22UA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, 22UA is valued cheaply inside the industry as 80.56% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 25.12
EV/EBITDA N/A
22UA.DE Per share data22UA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

A cheap valuation may be justified as 22UA's earnings are expected to decrease with -42.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.23%
EPS Next 3Y-42.65%

More info and screens

0

5. Dividend

5.1 Amount

22UA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

FRA:22UA (3/7/2025, 7:00:00 PM)

101.6

-2.5 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)N/A N/A
Inst Owners22.06%
Inst Owner ChangeN/A
Ins Owners2.04%
Ins Owner ChangeN/A
Market Cap24.36B
Analysts79.26
Price Target134.32 (32.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.04%
Min EPS beat(2)-62.82%
Max EPS beat(2)150.91%
EPS beat(4)1
Avg EPS beat(4)11.69%
Min EPS beat(4)-62.82%
Max EPS beat(4)150.91%
EPS beat(8)5
Avg EPS beat(8)271.9%
EPS beat(12)8
Avg EPS beat(12)194.11%
EPS beat(16)12
Avg EPS beat(16)219.92%
Revenue beat(2)1
Avg Revenue beat(2)47.3%
Min Revenue beat(2)-13.02%
Max Revenue beat(2)107.62%
Revenue beat(4)1
Avg Revenue beat(4)4.24%
Min Revenue beat(4)-56.98%
Max Revenue beat(4)107.62%
Revenue beat(8)2
Avg Revenue beat(8)-8.54%
Revenue beat(12)5
Avg Revenue beat(12)4.91%
Revenue beat(16)9
Avg Revenue beat(16)15.52%
PT rev (1m)-1.13%
PT rev (3m)0.42%
EPS NQ rev (1m)-7.89%
EPS NQ rev (3m)-34.64%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-2.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.01
P/FCF 25.12
P/OCF 16.01
P/B 1.27
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)4.04
FCFY3.98%
OCF(TTM)6.35
OCFY6.25%
SpS12.68
BVpS79.73
TBVpS74.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.08%
ROE -2.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.71%
FCFM 31.9%
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)61.51%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.25
Debt/EBITDA N/A
Cap/Depr 261.47%
Cap/Sales 18.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.33
Quick Ratio 7.21
Altman-Z 6.5
F-Score2
WACC7.08%
ROIC/WACCN/A
Cap/Depr(3y)295.05%
Cap/Depr(5y)262.38%
Cap/Sales(3y)7.13%
Cap/Sales(5y)20.83%
Profit Quality(3y)216.26%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
EPS Next Y-185.35%
EPS Next 2Y-70.23%
EPS Next 3Y-42.65%
EPS Next 5Y-17.8%
Revenue 1Y (TTM)-54.07%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%
Revenue Next Year-38.23%
Revenue Next 2Y-22.56%
Revenue Next 3Y-15.83%
Revenue Next 5Y-4.48%
EBIT growth 1Y-120.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-207.46%
EBIT Next 3Y-45.09%
EBIT Next 5Y-6.64%
FCF growth 1Y-92.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.88%
OCF growth 3YN/A
OCF growth 5YN/A